Literature DB >> 7512763

The pore-forming peptide of Entamoeba histolytica, the protozoan parasite causing human amoebiasis.

M Leippe1, H J Müller-Eberhard.   

Abstract

Amoebapore, the pore-forming peptide of E. histolytica has been isolated and its structure elucidated on the cDNA and protein level. The peptide is composed of 77 amino acid residues including six cysteine residues and has a molecular mass of 8244 Da. The primary translation product contains a signal sequence of 21 mostly hydrophobic amino acid residues. The active peptide has been located in the cytoplasmic granules of the amoebae. Circular dichroism spectroscopy revealed an all alpha-helical conformation and computer-aided secondary structure prediction yielded a structure of four helices. The helical conformation and three intramolecular disulfide bonds impart a highly compact and rigid structure upon the molecule. The activity of amoebapore, measured by a liposome depolarization assay, is resistant to heating at 100 degrees C in the absence of reducing agents. Synthetic peptides corresponding to the helices 1 and 3 exhibited pore-forming activity. Two minor, biologically active isoforms of amoebapore have amino acid sequence identity of 57% and 47%, respectively. Whereas amoebapore is a constituent of pathogenic E. histolytica isolates, nonpathogenic E. histolytica produce a structurally very similar peptide, the specific activity of which is approximately one third that of amoebapore. The biological significance of amoebapore for the pathogenicity of E. histolytica and specifically for its cytolytic activity remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512763     DOI: 10.1016/0300-483x(94)90151-1

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  9 in total

1.  Amoebapores and NK-lysin, members of a class of structurally distinct antimicrobial and cytolytic peptides from protozoa and mammals: a comparative functional analysis.

Authors:  Heike Bruhn; Beate Riekens; Otto Berninghausen; Matthias Leippe
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

2.  The invasiveness of Entamoeba histolytica - a continuing enigma.

Authors:  J P Ackers
Journal:  Clin Mol Pathol       Date:  1996-08

Review 3.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

4.  Partial immunity to Fasciola hepatica in mice after vaccination with FhSAP2 delivered as recombinant protein or DNA construct.

Authors:  Ana M Espino; Adelaida Morales; Bonnibel Delgado; Francheska M Rivera; Olgary Figueroa; Erick Suárez
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

5.  Identification and gene expression analysis of a large family of transmembrane kinases related to the Gal/GalNAc lectin in Entamoeba histolytica.

Authors:  David L Beck; Douglas R Boettner; Bojan Dragulev; Kim Ready; Tomoyoshi Nozaki; William A Petri
Journal:  Eukaryot Cell       Date:  2005-04

6.  Necrosis versus apoptosis as the mechanism of target cell death induced by Entamoeba histolytica.

Authors:  O Berninghausen; M Leippe
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

Review 7.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

8.  Host-parasite interaction: parasite-derived and -induced proteases that degrade human extracellular matrix.

Authors:  Carolina Piña-Vázquez; Magda Reyes-López; Guillermo Ortíz-Estrada; Mireya de la Garza; Jesús Serrano-Luna
Journal:  J Parasitol Res       Date:  2012-06-26

9.  Proteases from Entamoeba spp. and Pathogenic Free-Living Amoebae as Virulence Factors.

Authors:  Jesús Serrano-Luna; Carolina Piña-Vázquez; Magda Reyes-López; Guillermo Ortiz-Estrada; Mireya de la Garza
Journal:  J Trop Med       Date:  2013-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.